Business Wire

SDS (Software Daten Service) Achieves Oracle Exadata Optimized Status

2.11.2020 15:30:00 EET | Business Wire | Press release

Share

SDS today announced it has earned Oracle Exadata Optimized status through Oracle PartnerNetwork (OPN), demonstrating that SDS GEOS 7.9.0 has been tested and tuned on Oracle Exadata Database Machine to deliver speed, scalability, and reliability to customers. SDS is a Platinum level member of OPN.

Only a few companies manage to set new digital standards with the disruptive change happening in the financial industry and at the same time guarantee security in maximum performance dimensions. As part of a proof of concept (PoC) conducted at the Oracle Solutions Center, the throughput of SDS GEOS securities order processing was measured. The test of SDS GEOS 7.9.0 was conducted on an Oracle Exadata X8M configured as a database system with a two-node RAC, with a total of 32 CPU cores and 64GB memory assigned to the workload, which resulted in a more than convincing throughput of 795.9 orders/sec compared to the currently acceptable 100 to 400 orders per second. This clearly demonstrates that SDS GEOS runs very efficiently on Oracle Exadata Database Machine and that SDS is a future-proof and secure partner for the highest workloads.

Oracle Exadata Optimized is part of the Oracle Exastack Optimized program which enables partners, such as SDS, to leverage OPN enablement resources and dedicated lab environments to help develop, test, and tune their applications on Oracle Exadata engineered systems.

By achieving Oracle Exadata Optimized status, Oracle recognizes SDS for developing, testing, and tuning SDS GEOS on Oracle Exadata. This accomplishment is a testament to SDS’s ability to deliver the extreme performance and reliability customers require.

"Together with Oracle, SDS was able to test a new performance dimension in the processing of securities orders. This is a very important indicator that shows the limits of the performance of banking systems and associated transaction service providers can be surpassed, especially when needed in a volatile and strongly crisis-driven trading environment. A level of around 100 to 400 orders per second is usually sufficient for large securities traders in the most significant financial markets in Europe to guarantee their customers an immediate dispatch to the trading center even in times of extremely high order volumes. This requirement was outperformed by up to 700% in our laboratory test, providing clear evidence that SDS GEOS runs very efficiently on Oracle and that SDS is a future-proof and secure partner for the highest workloads in this technology stack," comments SDS Managing Director Ernst Kendlbacher on the results for Oracle Exastack Optimized.

“Oracle Exastack Optimized recognizes partners who have optimized their solutions on a complete, integrated and cloud-ready infrastructure in order to help them accelerate innovation, unlock new features and functionality, and deliver superior value to users,” said David Hicks, Vice President, Worldwide ISV Ecosystem Business Development, Oracle. “By achieving Oracle Exadata Optimized status, SDS has demonstrated that SDS GEOS is tested and tuned to work with Oracle Exadata to help deliver optimum performance, scalability, and reliability to their customers.”

To find out more, please visit http://www.sds.at or http://www.oracle.com/partners/goto/exastack or http://www.oracle.com/partners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rückfragehinweise / Press Contact:
HERBERT REINISCH
Marketing Manager Europe
Software Daten Service Gesellschaft m.b.H.
Rennweg 97-99, 1030 Vienna, Austria
Mobile: +43 676 88241 5188
herbert.reinisch@sds.at

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release

The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release

Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye